Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of First-line Etoposide/Platinum-based Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in Extensive Small Cell Lung Cancer: A Single-arm, Multicentral Phase II Study

Next Previous
X
Search
Trial Profile

Efficacy and Safety of First-line Etoposide/Platinum-based Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in Extensive Small Cell Lung Cancer: A Single-arm, Multicentral Phase II Study

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Catequentinib (Primary) ; Cisplatin (Primary) ; Etoposide (Primary) ; Toripalimab (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Shanghai Junshi Biosciences

    • Most Recent Events

    • 09 Aug 2022 Results (n=15; As of Feb 10, 2022) assessing efficacy and safety of anlotinib combined with toripalimab as maintenance treatment in extensive-stage small cell lung cancer, presented at the 2022 World Conference on Lung Cancer.
    • 10 Apr 2021 Status changed from not yet recruiting to recruiting, as per trial design presented at the 112th Annual Meeting of the American Association for Cancer Research
    • 10 Apr 2021 Trial design, presented at the 112th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top